Search
Resolvin E1
go.drugbank.com/drugs/DB13105InvestigationalResolvin E1 (RX 10001) is under investigation in clinical trial NCT00941018 (Single and Multiple Ascending Oral Dose Study of Resolvin E1 in Healthy Volunteers).
Pentostatin
go.drugbank.com/drugs/DB00552ApprovedInvestigationalThe drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. … It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
Synonyms: Co-vidarabinePhenacetin
go.drugbank.com/drugs/DB03783ApprovedWithdrawnPhenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).
Categories: Analgesics, Non-NarcoticCannabidivarin
go.drugbank.com/drugs/DB14050InvestigationalIn October 2017 CBDV was given orphan designation by the European Medicines Agency for use in Rett Syndrome [L2952] and again in February 2018 for treatment of Fragile X Syndrome [L2951]. … They will continue to study its use in epilepsy, however, and are expanding their investigations to include its potential use in Autism Spectrum Disorder, Rett syndrome and Fragile X among others [L2949
Synonyms: 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-propylbenzene-1,3-diolGinsenoside Rd
go.drugbank.com/drugs/DB19256InvestigationalGinsenoside Rd is under investigation in clinical trial NCT00815763 (Efficacy and Safety of Ginsenoside-rd for Acute Ischemic Stroke).
Synonyms: -d-glucopyranosyloxy)-12-hydroxydammar-24-en-3-yl 2-o-.beta.-d-glucopyranosyl-, Ginsenoside RdAluminum zirconium pentachlorohydrex gly
go.drugbank.com/drugs/DB11277ApprovedWithdrawnIt is a coordination complex of Aluminum Zirconium pentachlorohydrate and glycine. Its anhydrous form allows the molecule to absorb moisture. … Aluminum zirconium pentachlorohydrex gly, or Aluminum Zirconium Tetrachlorohydrex Glycine, is commonly used as an antiperspirant in many deodorant products.
RESP301
go.drugbank.com/drugs/DB16497InvestigationalAdditionally, RESP301 was investigated in a withdrawn trial (NCT04842331) for preventing viral exposure and transmission of COVID-19 and in a not yet recruiting trial (NCT04386070) for preventing pulmonary … RESP301 was under investigation in clinical trials for various conditions.
Categories: Experimental Unapproved Treatments for COVID-19Botulinum toxin type B
go.drugbank.com/drugs/DB00042ApprovedThe protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. … The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps.